SCHEMBL19009208

SCHEMBL19009208

c1ccc2c(c1)-c1ccccc1C21c2ccccc2-c2cccnc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MEN1 O00255 2/20 0.41
KDM4E B2RXH2 2/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
OPRK1 P41145 1/20 0.41
PDK2 Q15119 5/20 0.41
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 1/20 0.40
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38
PTPRC P08575 2/20 0.36
CTSL P07711 1/20 0.36
CTSS P25774 1/20 0.36
PTPN13 Q12923 1/20 0.36
TDP1 Q9NUW8 3/20 0.35
THRB P10828 2/20 0.35
TDP2 O95551 1/20 0.35
NSD2 O96028 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30322773 1.00 KMT2A (0.41) KMT2ASMN1; SMN2MEN1KDM4ELMNA
SCHEMBL19886866 0.90 PDK2 (0.38) KMT2ASMN1; SMN2MEN1KDM4ELMNA
SCHEMBL18174534 0.88 KMT2A (0.44) KMT2ASMN1; SMN2MEN1KDM4ELMNA
SCHEMBL20938307 0.88 PDK2 (0.34) KMT2ASMN1; SMN2MEN1KDM4ELMNA
SCHEMBL22085469 0.88 ALDH1A1 (0.38) KMT2ASMN1; SMN2MEN1KDM4ELMNA
SCHEMBL19980423 0.86 ALDH1A1 (0.39) KMT2ASMN1; SMN2MEN1KDM4ELMNA
SCHEMBL19567023 0.86 ALDH1A1 (0.39) KMT2ASMN1; SMN2MEN1KDM4ELMNA
SCHEMBL20938318 0.82 ALDH1A1 (0.35) KMT2ASMN1; SMN2MEN1KDM4ELMNA
SCHEMBL22424773 0.81 PDK2 (0.40) KMT2ASMN1; SMN2MEN1KDM4ELMNA
SCHEMBL18119650 0.80 KDM4E (0.41) KMT2ASMN1; SMN2MEN1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210163411-A1 COMPOUND HAVING TRIARYLAMINE STRUCTURE AS CORE, AND PREPARATION METHOD THEREFOR JIANGSU SUNERA TECHNOLOGY CO., LTD. (CN) 2021-06-03 US disclosed
US-10597403-B2 Condensed cyclic compound, composition including the condensed cyclic compound, organic light-emitting device including the condensed cyclic compound, and method of manufacturing the organic light-emitting device SAMSUNG ELECTRONICS CO., LTD. (KR) 2020-03-24 US disclosed
EP-3184522-A1 CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE CONDENSED CYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND, AND METHOD OF MANUFACTURING THE ORGANIC LIGHT-EMITTING DEVICE Samsung Electronics Co., Ltd. (KR) 2017-06-28 EP disclosed
US-20170174705-A1 CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE CONDENSED CYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND, AND METHOD OF MANUFACTURING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG ELECTRONICS CO., LTD. (KR) 2017-06-22 US disclosed
US-20170174705-A1 CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE CONDENSED CYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND, AND METHOD OF MANUFACTURING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG ELECTRONICS CO., LTD. (KR) 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174705-A1 CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE CONDENSED CYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND, AND METHOD OF MANUFACTURING THE ORGANIC LIGHT-EMITTING DEVICE CRY1, C9, CRY2 KMT2A 2550/4885SMN1; SMN2 3713/4885MEN1 623/4885
US-20210163411-A1 COMPOUND HAVING TRIARYLAMINE STRUCTURE AS CORE, AND PREPARATION METHOD THEREFOR WEE1, WEE2, ALOX12 KMT2A 1696/4885SMN1; SMN2 4092/4885MEN1 2066/4885
US-10597403-B2 Condensed cyclic compound, composition including the condensed cyclic compound, organic light-emitting device including the condensed cyclic compound, and method of manufacturing the organic light-emitting device CRY1, C9, CRY2 KMT2A 2550/4885SMN1; SMN2 3713/4885MEN1 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.